Ivonescimab

TrialFetch AI summary: Adults with advanced or recurrent MET exon 14–skipping NSCLC receive tepotinib, a MET inhibitor, plus investigational ivonescimab, a bispecific antibody targeting PD-1 and VEGF-A. Prior MET inhibitors and checkpoint inhibitors are permitted; the study focuses on safety and identifying a tolerable tepotinib dose.

ClinicalTrials.gov ID: NCT07619339

TrialFetch AI summary: Adults with advanced or metastatic nonsquamous NSCLC harboring an EGFR sensitizing mutation or ALK, ROS1, RET, or NTRK fusion receive ivonescimab after genotype-appropriate targeted therapy and platinum/pemetrexed. A separate chemotherapy-naive cohort without EGFR-mutated disease receives ivonescimab plus carboplatin/pemetrexed after targeted therapy; ivonescimab is an investigational bispecific antibody targeting PD-1 and VEGF-A.

ClinicalTrials.gov ID: NCT07405190

TrialFetch AI summary: Adults with squamous or nonsquamous NSCLC, at least one SRS-eligible brain metastasis (1.0–3.5 cm), and ECOG performance status 0–1 receive chemotherapy plus ivonescimab, a bispecific antibody targeting PD-1 and VEGF-A, followed by three-fraction SRS. The study evaluates a tolerable ivonescimab dose and 3-month intracranial disease control.

ClinicalTrials.gov ID: NCT07535463

TrialFetch AI summary: Adults with metastatic NSCLC harboring an osimertinib-sensitive EGFR mutation who have progressed after a third-generation EGFR TKI and received platinum chemotherapy or are ineligible for it receive ivonescimab, a PD-1/VEGF-A bispecific antibody, plus either datopotamab deruxtecan, a TROP2-directed topoisomerase I inhibitor antibody–drug conjugate, or osimertinib.

ClinicalTrials.gov ID: NCT07535437

TrialFetch AI summary: Adults with unresectable or metastatic leiomyosarcoma and measurable disease are eligible after 1–3 prior systemic therapy lines, or if they declined standard first-line therapy; prior PD-1/PD-L1 or VEGF inhibitor treatment is excluded. Participants receive ivonescimab, an investigational bispecific antibody targeting PD-1 and VEGF-A, intravenously every 3 weeks.

ClinicalTrials.gov ID: NCT07516925

TrialFetch AI summary: Adults with ECOG 0–1 and advanced or metastatic RAS-mutant solid tumors are eligible; expansion cohorts include untreated nonsquamous NSCLC and previously treated solid tumors or colorectal cancer. Treatment pairs ivonescimab (PD-1/VEGF-A bispecific antibody) with a RAS(ON) inhibitor—daraxonrasib (multiple RAS variants), elironrasib (KRAS G12C), or zoldonrasib (KRAS G12D)—with selected cohorts adding platinum–pemetrexed, daraxonrasib, or cetuximab.

ClinicalTrials.gov ID: NCT07397338

TrialFetch AI summary: This trial enrolls patients with unresectable metastatic colorectal cancer who have ECOG performance status 0–1 and have not received systemic therapy for metastatic disease; MSI-H/dMMR and BRAF V600E–mutant disease are excluded. Patients receive mFOLFOX6 followed by fluorouracil/leucovorin maintenance, with either ivonescimab, a bispecific antibody targeting PD-1 and VEGF-A, or bevacizumab.

ClinicalTrials.gov ID: NCT07228832

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic HER2-negative esophageal, gastroesophageal junction, or gastric adenocarcinoma who have not received treatment for advanced disease receive first-line ivonescimab plus FOLFOX. Ivonescimab is a bispecific antibody targeting PD-1 and VEGF-A; it is given alone for the first treatment, with FOLFOX added from cycle 2 onward.

ClinicalTrials.gov ID: NCT07070466

TrialFetch AI summary: Adults with previously treated metastatic colorectal adenocarcinoma receive ivonescimab, an investigational bispecific antibody targeting PD-1 and VEGF-A. Cohorts include dMMR/MSI-H disease progressing after PD-1/PD-L1 therapy and pMMR/MSS disease, with or without active liver metastases, progressing after or intolerant to fluoropyrimidine, irinotecan, and oxaliplatin.

ClinicalTrials.gov ID: NCT06959550

TrialFetch AI summary: Adults with untreated extensive-stage small cell lung cancer, measurable disease, and ECOG performance status 0–1 receive first-line carboplatin/etoposide plus either 10 or 20 mg/kg of ivonescimab, followed by ivonescimab maintenance. Ivonescimab is a bispecific antibody targeting PD-1 and VEGF-A; there is no chemotherapy-only arm.

ClinicalTrials.gov ID: NCT07057791

TrialFetch AI summary: Adults with advanced or metastatic clear cell RCC that has progressed after PD-1/PD-L1 inhibitor therapy receive ivonescimab, an intravenous bispecific antibody targeting PD-1 and VEGF-A, every three weeks. One cohort has had no prior VEGF- or HIF-2α-directed therapy; the other has progressed on or after VEGF-directed therapy.

ClinicalTrials.gov ID: NCT06940518

TrialFetch AI summary: Adults with measurable recurrent or metastatic endometrial or cervical cancer that has progressed after at least one platinum-based regimen receive ivonescimab, a bispecific antibody targeting PD-1 and VEGF-A. Prior PD-1 or VEGF-directed therapy is permitted.

ClinicalTrials.gov ID: NCT06925724

TrialFetch AI summary: Adults with previously untreated stage IV squamous or nonsquamous NSCLC, PD-L1 tumor proportion score >50%, and ECOG performance status 0–1 are randomized to intravenous ivonescimab or pembrolizumab. Ivonescimab is an investigational bispecific antibody targeting PD-1 and VEGF-A.

ClinicalTrials.gov ID: NCT06767514

TrialFetch AI summary: Adults with recurrent, metastatic, or unresectable salivary gland carcinoma, including adenoid cystic carcinoma, who have ECOG 0–1 and recent progression or worsening symptoms receive single-agent ivonescimab every 21 days. Ivonescimab is an investigational bispecific antibody targeting PD-1 and VEGF-A; prior anti–PD-1 therapy or oral VEGFR tyrosine kinase inhibitors are not permitted.

ClinicalTrials.gov ID: NCT06805617

TrialFetch AI summary: Adults with unresectable or metastatic cutaneous squamous cell carcinoma refractory to anti-PD-1 therapy receive intravenous ivonescimab every 21 days. Ivonescimab is an investigational bispecific antibody targeting PD-1 and VEGF-A.

ClinicalTrials.gov ID: NCT06567314

TrialFetch AI summary: Adults with previously untreated stage IV squamous or nonsquamous NSCLC, ECOG 0–1, and no actionable alterations with approved first-line therapies are randomized to chemotherapy plus either ivonescimab or pembrolizumab. Ivonescimab is an investigational bispecific antibody targeting PD-1 and VEGF-A.

ClinicalTrials.gov ID: NCT05899608